Menu
Search
|

Menu

Close
X

HTG Molecular Diagnostics Inc HTGM.OQ (NASDAQ Stock Exchange Capital Market)

3.31 USD
+0.14 (+4.42%)
As of Jul 21
chart
Previous Close 3.17
Open 3.15
Volume 24,488
3m Avg Volume 97,579
Today’s High 3.33
Today’s Low 3.15
52 Week High 5.82
52 Week Low 1.59
Shares Outstanding (mil) 11.45
Market Capitalization (mil) 21.52
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.33 Mean rating from 3 analysts

KEY STATS

Revenue (mm, USD)
FY18
4
FY17
15
FY16
5
FY15
4
EPS (USD)
FY18
-0.218
FY17
-1.939
FY16
-3.674
FY15
-4.057
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
3.91
5.73
Price to Book (MRQ)
vs sector
--
5.47
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
--
16.84
LT Debt to Equity (MRQ)
vs sector
--
12.51
Return on Investment (TTM)
vs sector
-158.24
14.61
Return on Equity (TTM)
vs sector
-1,928.83
16.34

EXECUTIVE LEADERSHIP

Ann Hanham
Independent Chairman of the Board, Since 2017
Salary: --
Bonus: --
John Lubniewski
President, Chief Operating Officer, Since 2018
Salary: $299,614.00
Bonus: --
Timothy Johnson
Chief Executive Officer, Director, Since 2018
Salary: $400,000.00
Bonus: --
Shaun McMeans
Vice President of Finance and Administration, Chief Financial Officer, Since 2012
Salary: $226,362.00
Bonus: --
Patrick Roche
Senior Vice President - Research and Product Development, Since 2014
Salary: $257,250.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Advanced Medical Equipment & Technology
Address:

3430 E Global Loop
TUCSON   AZ   85706-5009

Phone:

HTG Molecular Diagnostics, Inc. is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company's HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development. The Company's HTG Edge and HTG EdgeSeq platforms automate the molecular profiling of genes and gene activity using its nuclease protection chemistry on a range of biological samples. The Company's HTG EdgeSeq chemistry, together with its HTG Edge or HTG EdgeSeq instrumentation and software, automates and adapts its nuclease protection chemistry to enable analysis using next generation sequencing (NGS) instrumentation. The HTG EdgeSeq system utilizes substantially the same sample preparation reagents as its original chemistry, but allows for read out on an NGS instrument.

SPONSORED STORIES